Drug Profile
PDS 0101
Alternative Names: PDS 101; PDS-0101; PDS-0101C; PDS0101A; PDS0101B; Versamune-HPV; Versamune®-HPV16Latest Information Update: 17 Nov 2023
Price :
$50
*
At a glance
- Originator PDS Biotechnology Corporation
- Developer Merck & Co; National Cancer Institute (USA); PDS Biotechnology Corporation
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Peptide vaccines
- Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants; Interferon gamma stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Anal cancer; Anal intraepithelial neoplasia; Cancer; Cervical cancer; Cervical intraepithelial neoplasia; Head and neck cancer; Oropharyngeal cancer; Penile cancer; Rectal cancer; Squamous cell cancer; Vulvovaginal cancer
Most Recent Events
- 14 Nov 2023 PDS Biotech plans the registrational phase III VERSATILE-003 trial in Head and neck cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable, Recurrent), in the first quarter of 2024
- 20 Oct 2023 Efficacy data from the phase II VERSATILE-002 trial in Head and neck cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 03 Oct 2023 Updated efficacy and adverse events data from the phase II VERSATILE-002 trial in Squamous cell cancer released by PDS Biotechnology Corporation